Early trial tests new tablet to help IPF patients breathe
NCT ID NCT07036029
Summary
This is an early safety study for people with idiopathic pulmonary fibrosis (IPF). Researchers want to see if taking increasing doses of a long-acting tablet called nalbuphine ER is safe and if it affects breathing. The study will involve about 10 participants and will closely monitor their breathing and any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
Medicines Evaluation Unit Ltd.
RECRUITINGManchester, M23 9QZ, United Kingdom
Conditions
Explore the condition pages connected to this study.